LeadArtis discloses ATTACK, a novel bispecific T cell-recruiting antibody approach for cancer immunotherapy


LeadArtis´scientists, in collaboration with other prime research institutions, have developed a new tactic to generate multispecific T-cell recruiting antibodies to eradicate cancers.

The redirection of T cell activity using bispecific antibodies is one of the most promising cancer immunotherapy approaches currently in development, but it is limited by cytokine storm-related toxicities, as well as the pharmacokinetics and tumor-penetrating capabilities of current bispecific antibody formats. We have engineered the ATTACK (Asymmetric Tandem Trimerbody for T cell Activation and Cancer Killing), a novel T cell-recruiting bispecific antibody which combines three Tumor Associated Antigen (TAA) binding single-domain antibodies with a single CD3-binding domain in an intermediate molecular weight package. The two specificities are oriented in opposite directions in order to simultaneously engage cancer cells and T cell effectors, and thereby promote immunological synapse formation. The ATTACK molecules are expressed as homogenous, non-aggregating, soluble proteins by mammalian cells and demonstrated an enhanced binding to the TAA but not CD3. The ATTACKs demonstrated extremely potent, dose-dependent cytotoxicity when retargeting human T cells towards TAA-expressing cells. These results suggest that the ATTACK is an ideal format for the development of the next-generation of T cell-redirecting bispecific antibodies.

The paper is online. Please visit (http://www.tandfonline.com/doi/full/10.1080/2162402X.2017.1377874), download and share with your colleagues

Latest News

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for...
LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018...
Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer...